Skip to main content
Premium Trial:

Request an Annual Quote

Axys, Roche Bioscience Enter Genomics Alliance

Premium

PALO ALTO, Calif.--Drug discovery company Roche Biosciences here announced it has formed an alliance with Axys Pharmaceuticals of South San Francisco, Calif., to utilize Axys's functional genomics capabilities. Axys will apply its technologies utilizing C. elegans to evaluate the function of genes provided by Roche that may serve as drug targets in the development of therapies for pain and other nervous system disorders.

Roche will pay Axys an upfront fee and provide funding for research support. Axys has granted Roche an option to license targets discovered during the collaboration for the development of small molecule, diagnostic, and antisense products, with license payments, milestones, and royalties payable to Axys. Axys may also retain rights to develop gene therapy and therapeutic protein products acting upon targets discovered during the collaboration.

Filed under

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.